KeyBanc analyst Paul Knight raised the firm's price target on Cryoport to $17 from $15 and keeps an Overweight rating on the shares. The firm believes the company's revenue visibility is higher and quality is better than the COVID era, and margins are likely to expand through 2028. The core Service Group has a long runway for revenue growth, with 18 commercial customers growing 20% through 2028 and 760 clinical customers, KeyBanc adds.
